Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
206 : 587595 Curti D, Dagani F, Galmozzi MR, Marzatico F
This could include: Heart rate assessment at 4-8 weeks after initiation or dose escalation Periodic electrocardiography if arrhythmias are suspected Patient self-monitoring of pulse if symptomatic palpitations occur Evaluation of heart rate control in patients with atrial fibrillation When evaluating tachycardia in patients on GLP-1 therapy, clinicians should assess for other potential causes, including dehydration (especially from GI side effects), anemia, hyperthyroidism, stimulant use, infection, or other medications
D., Butler, M
Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, et al
US$ 20.29
US$ 26.18
US$ 20.71
US$ 24.05
US$ 28.11
US$ 24.74
US$ 22.42
